Pharmaceutical
Biopharmaceutical
Manufacturing

Bristol-Myers Squibb

$47.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.49 (-1.04%) Today
+$0.45 (0.97%) After Hours

Why Robinhood?

You can buy or sell BMY and other stocks, options, ETFs, and crypto commission-free!

About

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. Read More The company was founded in August 1933 and is headquartered in New York, NY.

Employees
23,300
Headquarters
New York, New York
Founded
1933
Market Cap
77.38B
Price-Earnings Ratio
14.81
Dividend Yield
3.10
Average Volume
11.82M
High Today
$47.54
Low Today
$46.79
Open Price
$47.41
Volume
3.01M
52 Week High
$63.69
52 Week Low
$44.30

Collections

Pharmaceutical
Biopharmaceutical
Manufacturing
Research And Development
Health
Biotechnology
Technology
Business Services

News

BenzingaMay 22

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what immunotherapy means: it's a type of cancer treatment that uses the body's immune system to put up a fight against cancer cells. Merck's Keytruda, or pembrolizumab, and BMY's Opdivo, or nivolumab, are both human, programmed deat...

322
Seeking AlphaMay 22

Bristol-Myers Squibb: Share Repurchases No Benefit To Shareholders

The reason for this dichotomy - the only way an investor can realize a return from an investment in shares is through receipt of dividends, and/or gains on sales, regardless of company performance.

73
Yahoo FinanceMay 20

Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines

Bristol-Myers Squibb Co (NYSE: BMY)'s quest to expand its oncology franchise through its proposed acquisition of Celgene Corporation (NASDAQ: CELG) may not be a wise move, according to Argus.

314

Earnings

$0.67
$0.81
$0.96
$1.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 25, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.